Literature DB >> 10756369

Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica.

D De Mattia1, D Del Principe, G C Del Vecchio, M Jankovic, A Arrighini, P Giordano, A Menichelli, P Mori, M Zecca, A Pession.   

Abstract

BACKGROUND AND
OBJECTIVE: A recent evaluation carried out by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) about practice management of acute childhood idiopathic thrombocytopenic purpura (ITP) revealed a remarkable difference of behaviors among the different AIEOP centers. A need for common practice guidelines for this frequent illness arose from this observation. Our aim was to make the diagnosis and treatment of childhood ITP uniform. In the future we will evaluate the influence of these guidelines on practice behaviors. DATA SOURCES AND METHODS: Our main reference was the 1996 document produced by the American Society of Hematology (ASH). Their recommendations were updated with information from literature searched for in the MEDLINE database (June 1996-October 1998); search terms included: thrombocytopenia, ITP, diagnosis, therapy, children. The computerized search retrieved 83 articles. DATA EXTRACTION: the scientific validity of the literature was evaluated by a panel of members using published guidelines. The strength of the evidence was assessed using level of evidence criteria. Only data from level I and level II studies were taken in account. Only one study out of the 83 retrieved articles met these selection criteria and it was considered in addition to the 11 out of 581 articles selected in the ASH ITP guidelines. This preliminary work pointed out each issue about ITP not addressed by clinical studies and all participants in a Consensus Conference expressed their opinion about these issues.
RESULTS: Diagnosis is essentially based on history, physical examination, a complete blood count and an examination of the peripheral blood smear. Treatment is recommended taking into account the clinical picture and number of platelets. The main difference between these guidelines and those from ASH are: AIEOP guidelines rely on the opinion of the members of the consensus conference, ASH ones on a panel of experts; therapeutic options include only products available in Italy; the indications to treatment rely more on clinical picture than on platelet number. INTERPRETATION AND
CONCLUSIONS: These are explicitly developed, evidence-based practice guidelines to assist Italian pediatricians in making decisions about diagnosis and appropriate health care for patients with acute childhood ITP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756369

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

Review 1.  Genetic studies in pediatric ITP: outlook, feasibility, and requirements.

Authors:  Anke K Bergmann; Rachael F Grace; Ellis J Neufeld
Journal:  Ann Hematol       Date:  2010-03-23       Impact factor: 3.673

2.  Consensus guideline for diagnosis and treatment of childhood idiopathic thrombocytopenic purpura.

Authors:  Akira Shirahata; Eiichi Ishii; Haruhiko Eguchi; Hiroji Okawa; Shigeru Ohta; Takashi Kaneko; Shozaburo Konishi; Masahiro Sako; Isao Sekine; Yukihiro Takahashi; Masashi Taki; Shigeru Tsuchiya; Kohji Fujisawa; Fumio Bessho; Yasuo Horikoshi; Junichi Mimaya; Jun-Ichi Akatsuka; Sumio Miyazaki
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

3.  Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population.

Authors:  Rachael F Grace; Michelle Long; Leslie A Kalish; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

Review 4.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

5.  CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura.

Authors:  Francesca Rossi; Silvia Mancusi; Giulia Bellini; Domenico Roberti; Francesca Punzo; Simona Vetrella; Sofia Maria Rosaria Matarese; Bruno Nobili; Sabatino Maione; Silverio Perrotta
Journal:  Haematologica       Date:  2011-08-09       Impact factor: 9.941

6.  Clinical significance of serum cytokine levels and thrombopoietic markers in childhood idiopathic thrombocytopenic purpura.

Authors:  Giovanni Carlo Del Vecchio; Paola Giordano; Riccardina Tesse; Laura Piacente; Maria Altomare; Domenico De Mattia
Journal:  Blood Transfus       Date:  2011-11-15       Impact factor: 3.443

7.  Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study.

Authors:  Emilia Parodi; Giovanna Russo; Piero Farruggia; Lucia D Notarangelo; Maria T Giraudo; Margherita Nardi; Fiorina Giona; Paola Giordano; Ugo Ramenghi; Angelica Barone; Gianluca Boscarol; Simone Cesaro; Francesca Fioredda; Saverio Ladogana; Maria Licciardello; Francesca Rossi; Laura Rubert; Marco Spinelli; Fabio Tucci
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

8.  B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy.

Authors:  Paola Giordano; Simona Cascioli; Giuseppe Lassandro; Valentina Marcellini; Fabio Cardinale; Federica Valente; Franco Locatelli; Rita Carsetti
Journal:  Pediatr Res       Date:  2015-10-22       Impact factor: 3.756

9.  Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.

Authors:  Mohamed E Osman
Journal:  Sudan J Paediatr       Date:  2012

10.  Efficacy of combined intravenous immunoglobulins and steroids in children with primary immune thrombocytopenia and persistent bleeding symptoms.

Authors:  Emilia Parodi; Paola Giordano; Elisa Rivetti; Maria Teresa Giraudo; Giulia Ansaldi; Mirella Davitto; Anna Mondino; Piero Farruggia; Giovanni Amendola; Sofia M R Matarese; Francesca Rossi; Giovanna Russo; Ugo Ramenghi
Journal:  Blood Transfus       Date:  2014-03-03       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.